1. Expression and agonist responsiveness of CXCR3 variants in human T lymphocytes
- Author
-
Malcolm L. Watson, Andrew J. McKnight, Zoë Johnson, Anna Korniejewska, and Stephen G. Ward
- Subjects
Immunology ,hemic and immune systems ,Biology ,CXCR3 ,Pertussis toxin ,Cell biology ,stomatognathic diseases ,Chemokine receptor ,stomatognathic system ,immune system diseases ,Cancer research ,Immunology and Allergy ,CXCL10 ,Signal transduction ,skin and connective tissue diseases ,Receptor ,Protein kinase B ,CXCL16 - Abstract
The chemokine receptor CXCR3 and its ligands CXCL9, CXCL10 and CXCL11 are involved in variety of inflammatory disorders including multiple sclerosis, rheumatoid arthritis, psoriasis and sarcoidosis. Two alternatively spliced variants of the human CXCR3-A receptor have been described, termed CXCR3-B and CXCR3-alt. Human CXCR3-B binds CXCL9, CXCL10, CXCL11 as well as an additional ligand CXCL4. In contrast, CXCR3-alt only binds CXCL11. We report that CXCL4 induces intracellular calcium mobilization as well as Akt and p44/p42 extracellular signal-regulated kinase phosphorylation, in activated human T lymphocytes. These responses have similar concentration dependence and time-courses to those induced by established CXCR3 agonists. Moreover, phosphorylation of Akt and p44/p42 is inhibited by pertussis toxin, suggesting coupling to Gα(i) protein. Surprisingly, and in contrast with the other CXCR3 agonists, stimulation of T lymphocytes with CXCL4 failed to elicit migratory responses and did not lead to loss of surface CXCR3 expression. Taken together, our findings show that, although CXCL4 is coupled to downstream biochemical machinery, its role in T cells is probably distinct from that of CXCR3-A agonists.
- Published
- 2011
- Full Text
- View/download PDF